Law360, New York (April 06, 2009, 12:00 AM ET) -- Genzyme Corp. has sued rival Impax Laboratories Inc. to stop it from making generic Renvela, three weeks after it sued Impax and another generic-drug maker over an earlier version of the same kidney treatment.
The Cambridge, Mass.-based drugmaker filed suit Friday in the U.S. District Court for the District of Maryland over U.S. Patent Number 5,667,775, which covers both Renvela and Renagel, its predecessor drug.
Genzyme filed the suit after learning Feb. 23 that Impax had submitted an abbreviated new drug application to the U.S. Food...
Genzyme Sues Impax Labs Over ANDA For Renvela
To view the full article, take a free trial now.
